New targeted drug SYS6043 enters human trials for Hard-to-Treat cancers

NCT ID NCT07415863

Recruiting now Disease control Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called SYS6043 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The trial will first find the safest dose, then expand to measure how well it shrinks tumors in up to 820 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SYS6043 (an antibody-drug conjugate targeting B7-H3)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is an early-phase trial (Phase I/II) with a small number of participants initially, so safety and effectiveness are not yet proven. Side effects from the drug are possible, and the results may not apply to all tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED/METASTATIC SOLID TUMORS

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.